Clinical trial · Observational
Incretin-based Drugs and Pancreatic Cancer
The Use of Incretin-based Drugs and the Risk of Pancreatic Cancer in Patients With Type 2 Diabetes
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine whether incretin-based drugs (used to treat type 2 diabetes) taken either alone in or combination with other anti-diabetic drugs are associated with an increased risk of pancreatic cancer (PC) compared to sulfonylureas. The investigators will carry out separate population based cohort studies using administrative health databases in five jurisdictions in Canada, the US, and the UK. Cohorts will be defined by the initiation of a new anti-diabetic drug when incretin-based drugs entered the market, with follow-up until hospitalization for PC. The results from the separate sites will be combined to provide an overall assessment of the risk of PC in users of incretin-based drugs and by class of incretin-based drugs.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Diabetes Mellitus, Type 2 | — | UNRESOLVED | — |
Interventions
Interventions (7)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Alpha-glucosidase inhibitors | Drug | — | UNRESOLVED |
| Biguanides | Drug | — | UNRESOLVED |
| DPP-4 inhibitors | Drug | — | UNRESOLVED |
| GLP-1 analogs | Drug | — | UNRESOLVED |
| Meglitinides | Drug | — | UNRESOLVED |
| Sulfonylureas | Drug | — | UNRESOLVED |
| Thiazolidinediones | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Treated with incretins
- description
- Ever-use of incretin-based drugs ((DPP-4 inhibitors \[sitagliptin, vildagliptin, and saxagliptin\] or GLP-1 analogs \[exenatide, liraglutide\]) between (and including) base cohort entry and the index day - 365 days.
- interventionNames
- Drug: DPP-4 inhibitors
- Drug: GLP-1 analogs
- label
- Treated with sulfonylureas
- description
- Ever-use of sulfonylureas between (and including) base cohort entry and the index day - 365 days, and never-use of incretin-based drugs.
- interventionNames
- Drug: Sulfonylureas
- label
- Treated with other antidiabetic agents
- description
- Ever-use of other antidiabetic agents (biguanides, thiazolidinediones, alpha-glucosidase inhibitors, meglitinides) between (and including) base cohort entry and the index day - 365 days, with never-use of incretin-based drugs and never use of sulfonylureas.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with a first-ever prescription for a non-insulin anti-diabetic drug, including biguanides, sulfonylureas, thiazolidinediones, DPP-4 inhibitors, GLP-1 analogs, alpha-glucosidase inhibitors, meglitinides or combinations of these drugs from the earliest availability of data at each site to the last date of availability of data. * Patients with at least 1 year of history in the database. * Patients at least 18 years of age. Exclusion Criteria: * Patients who died or left the cohort before the year the first incretin-based drug entered the market. * Patients who never added-on or switched to a new anti-diabetic drug after incretin-based drugs entered the market up until June 30, 2014. * Patients with a previous diagnosis of pancreatic cancer, those who underwent pancreatectomy or were diagnosed with congenital defects of the pancreas at any time prior to study cohort entry. * Patients with less than 365 days of follow-up after study cohort entry
References
Publications (1)
- RESULTAzoulay L, Filion KB, Platt RW, Dahl M, Dormuth CR, Clemens KK, Durand M, Juurlink DN, Targownik LE, Turin TC, Paterson JM, Ernst P; Canadian Network for Observational Drug Effect Studies Investigators. Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study. BMJ. 2016 Feb 17;352:i581. doi: 10.1136/bmj.i581. PMID 26888382